Trial Profile
Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cisplatin; Doxorubicin; Gemcitabine; Methotrexate; Paclitaxel; Vinblastine
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms AURA trial
- 28 Sep 2023 Planned End Date changed from 1 Dec 2022 to 31 Jan 2025.
- 28 Sep 2023 Status changed from completed to active, no longer recruiting.
- 27 Mar 2023 Status changed from active, no longer recruiting to completed.